Board of Directors
Anders Kapstad
Chairman
Anders Kapstad is CFO and Life Cycle Manager at Inven2. Anders holds a Bachelor of Science and MBA in Business and Finance. Result oriented executive with an international background and a comprehensive track-record from private and listed companies. Extensive background from Investment-Banking and CFO for publicly listed companies.
Frank Frantzen
Frank Frantzen was previously a Sr. Director R&D at Abbott Diagnostic Technology AS. He brings with him 35+ years of experience within the IVD industry and has held leading positions at Axis-Shield, Alere and Abbott.
Frank holds a PhD in biomedical chemistry/IVD-technology and has participated in launching several world class IVD products (both assays and instrumentation), for both PoC and core lab. His area of speciality covers exploratory research, product development, patenting, and R&D management.
Frank received Abbott’s Scientific Governing Board Innovation award in 2019, for his work on HbA1c – the reference marker for diabetes diagnosis and monitoring; a work crucial to Abbott’s position as world leader in PoC HbA1c testing.
Rizwan I. Hussain
Rizwan I. Hussain MD, PhD, received his MD degree in 2007 and PhD degree in molecular cardiology – heart failure in 2011, both from the University of Oslo, Norway. He is currently the CEO of Agiana Pharmaceuticals, a clinical stage biotechnology company developing a novel anti-arrhythmic therapy.
Over the last 10 years Rizwan has held a variety of senior positions within the pharmaceutical industry. He spent 7 years at Novartis where he had increasing responsibility within medical affairs and clinical development, including 2 years as Global Medical Director where he had oversight of global clinical trials and helped launch Entresto®, a blockbuster heart failure drug. In 2019 Rizwan co-founded Arxx Therapeutics, a biotech developing a monoclonal antibody for the treatment of fibrosis in which he was the CEO of to 2022. Rizwan joined the Board of CardiNor in 2023.